Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after 12 years of research [1] - Beimeijing® is the first and only topical gel approved for the treatment of "proliferative superficial infantile hemangiomas," marking a key advancement for China in this medical field [1] - The drug has received authoritative certification from the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Context - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The critical intervention period for effective treatment is within the first 1-6 months after birth, known as the "golden window," where timely treatment can prevent long-term skin issues [2] - Traditional treatment methods have faced limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - The development of Beimeijing® was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, involving a comprehensive process from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and non-invasive option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data supports the advantages of Beimeijing®, showing a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months, with good safety profiles [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the needs of children, ensuring that the standardized treatment approach is effectively communicated to families [3]

Group 1 - The core viewpoint of the article highlights the launch of a groundbreaking treatment for infantile hemangiomas in China, specifically the gel formulation of Timolol Maleate (brand name: Beimeijing®), which is the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas" globally [1][2] - Beimeijing® was developed by Beijing Melson Pharmaceutical Technology Co., Ltd. over a span of twelve years, marking a significant advancement in the treatment of this condition, transitioning China from a follower to a leader in this medical field [1][2] - The product was officially launched on Alibaba Health, allowing parents to access the treatment through an online consultation, thus enhancing the accessibility and convenience of care for families [1][3] Group 2 - The drug received approval from the National Medical Products Administration (NMPA) on September 30, 2025, and has been recognized by the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original drugs in the international market [1][2] - The clinical consensus emphasizes the importance of intervention during the "golden window period" of 1-6 months after birth, as untreated hemangiomas can lead to permanent skin issues, highlighting the need for effective treatment options [2] - The gel formulation allows for localized application, significantly reducing systemic exposure risks and enhancing safety for infants, compared to traditional treatments such as oral medications or surgical interventions [2][3] Group 3 - Phase III clinical trial data supports the efficacy and safety of Beimeijing®, showing a clinical cure rate of 60.7% and an overall effective rate of 89.4% among 121 infants aged 1-6 months [3] - Alibaba Health aims to create a comprehensive service ecosystem centered around the child, facilitating the delivery of standardized treatment solutions and long-term management for families in need [3]

Core Insights - A milestone solution for infant vascular tumor treatment has been launched in China, with the modified new drug, Malate Timolol Gel (brand name: Beimeijing), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1] - The drug is the first and only approved topical gel formulation for treating "proliferative superficial infantile hemangiomas," marking a significant advancement for China in this medical field [1] - Beimeijing has received national-level price certification, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Overview - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The "golden window period" for effective intervention is within the first 1-6 months after birth, as failure to treat during this period can lead to permanent skin issues [2] - Traditional treatment methods have limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - Beimeijing's development was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, with a comprehensive approach from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and pain-free option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data showed that among 121 infants aged 1-6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4% and good safety profile [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the child, ensuring that the standardized treatment approach represented by Beimeijing reaches every family in need [3]

Core Viewpoint - The Chinese pharmaceutical industry is undergoing a significant transformation, shifting from a focus on generic drugs to the rise of original research and development (R&D) drugs, driven by policy innovation, technological breakthroughs, and capital support [1][2]. Group 1: Policy and Regulatory Changes - The reform of the drug review and approval system in China is a long-term initiative aimed at addressing structural issues such as backlog in drug reviews and a high proportion of low-level generics [2]. - Since the 14th Five-Year Plan, a series of policy benefits have been released, establishing green channels for breakthrough therapies, conditional approvals, and priority reviews, which have greatly stimulated innovation [2]. - The average review time for drug clinical trials has decreased from 108 days in 2018 to 50 days in 2024, with pilot regions like Beijing and Shanghai reducing it to under 30 days for eligible innovative drugs [2]. Group 2: Innovation and Development - The R&D of innovative drugs in China has achieved significant advancements in both quantity and quality, with companies like Zhejiang Maitong Biopharmaceutical launching innovative drugs that fill international treatment gaps [3]. - The shift from follower innovation to original innovation is evident, with Chinese companies now capable of achieving optimal or even pioneering solutions in certain therapeutic areas [3]. Group 3: Market Access and Affordability - The optimization of the medical insurance access mechanism has significantly reduced the time from drug launch to inclusion in the insurance catalog, making innovative drugs more accessible to patients [4]. - Since the establishment of the National Medical Insurance Bureau in 2018, the number of approved innovative drugs has reached 265, with 68 approved in 2025 alone, over six times the total for 2018 [4]. - The introduction of early resolution mechanisms for patent disputes has encouraged innovation and investment in R&D [4]. Group 4: International Recognition and Expansion - Chinese original research drugs are gaining international recognition, with companies like BeiGene and CanSino Biologics developing competitive products that outperform international counterparts [5]. - The internationalization of Chinese pharmaceutical companies is deepening, with efforts to expand overseas markets and establish R&D centers abroad [5]. - The 15th Five-Year Plan emphasizes support for the development of innovative drugs and medical devices, aiming to integrate more Chinese innovations into the global pharmaceutical landscape [5].